1-4 of 4
Peter Öhman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial

M. Angelyn Bethel, Robert J. Mentz, Peter Merrill, John B. Buse, Juliana C. Chan, Shaun G. Goodman, Nayyar Iqbal, Neli Jakuboniene, Brian Katona, Yuliya Lokhnygina, Renato D. Lopes, Aldo P. Maggioni, Peter Ohman, Tsvetalina Tankova, George L. Bakris, Adrian F. Hernandez, Rury R. Holman
Journal: Diabetes Care
Diabetes Care 2020;43(2):446–452
https://doi.org/10.2337/dc19-1065
Published: 22 November 2019
View articletitled, Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
Open the PDF for Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial in another window
Includes: Supplementary data
Journal Articles

Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)

M. Angelyn Bethel, Rishi A. Patel, Vivian P. Thompson, Peter Merrill, Shelby D. Reed, Yanhong Li, Sara Ahmadi, Brian G. Katona, Stephanie M. Gustavson, Peter Ohman, Nayyar Iqbal, Robert F. Gagel, Adrian F. Hernandez, John B. Buse, Rury R. Holman
Journal: Diabetes Care
Diabetes Care 2019;42(6):1075–1080
https://doi.org/10.2337/dc18-2028
Published: 22 April 2019
View articletitled, Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
Open the PDF for Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) in another window
Includes: Supplementary data
Journal Articles

Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study

Matthew C. Riddle, Rajaa Nahra, Jenny Han, Jessica Castle, Kathryn Hanavan, Marcus Hompesch, David Huffman, Poul Strange, Peter Öhman
Journal: Diabetes Care
Diabetes Care 2018;41(11):2346–2352
https://doi.org/10.2337/dc18-1091
Published: 13 September 2018
View articletitled, Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study
Open the PDF for Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study in another window
Includes: Supplementary data
Journal Articles

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial

Serge A. Jabbour, Juan P. Frías, Elise Hardy, Azazuddin Ahmed, Hui Wang, Peter Öhman, Cristian Guja
Journal: Diabetes Care
Diabetes Care 2018;41(10):2136–2146
https://doi.org/10.2337/dc18-0680
Published: 06 August 2018
View articletitled, Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial
Open the PDF for Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial in another window
Includes: Supplementary data